Black Bird Biotech, Inc. (BBBT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.01: the stock has moved about 101% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBlack Bird Biotech, Inc. (BBBT) trades at $0.0001. Black Bird Biotech, Inc. operates in the biotech sector, focusing on biopesticides and CBD products. The company's MiteXstream targets spider mites, while its Grizzly Creek Naturals brand offers CBD-infused products. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for BBBT: BBBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Black Bird Biotech, Inc. (BBBT) Healthcare & Pipeline Overview
Black Bird Biotech, Inc. is a biotech company specializing in plant-based biopesticides and CBD products, including MiteXstream for spider mite eradication and the Grizzly Creek Naturals line of CBD oils and personal care items. The company also engages in industrial hemp cultivation under the Montana Hemp pilot program.
What Is the Investment Thesis for BBBT?
Black Bird Biotech, Inc. presents a high-risk, high-reward investment opportunity given its early stage and OTC market listing. The company's focus on MiteXstream, a plant-based biopesticide, addresses a growing demand for sustainable agricultural solutions. However, the company's negative profit margin of -2009.1% and gross margin of -67.7% indicate significant financial challenges. Future growth hinges on successful market penetration of MiteXstream and expansion of the Grizzly Creek Naturals CBD product line. The company's small size and limited resources, managing with only 4 employees, pose operational risks. Investors should closely monitor revenue growth, cost management, and regulatory developments in the biopesticide and CBD markets. The company's beta of 2.01 suggests high volatility.
Based on FMP financials and quantitative analysis
BBBT Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited financial resources.
- P/E Ratio of -0.02 reflects negative earnings and challenges in achieving profitability.
- Profit Margin of -2009.1% highlights significant losses relative to revenue.
- Gross Margin of -67.7% suggests that the cost of goods sold exceeds revenue, indicating pricing or production inefficiencies.
- Beta of 2.01 indicates higher volatility compared to the market, suggesting a riskier investment.
Who Are BBBT's Competitors?
BBBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GCAN The Greater Cannabis Company, Inc. | $1.60 | 0.00% | — | |
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $5.03 | +56.21% | $7.59M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.08 | +1.22% | $24.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BBBT's Key Strengths?
Proprietary plant-based biopesticide (MiteXstream).
- Established CBD brand (Grizzly Creek Naturals).
- Participation in Montana Hemp pilot program.
- Focus on sustainable and environmentally friendly products.
What Are BBBT's Weaknesses?
Negative profit and gross margins.
- Limited financial resources.
- Small number of employees (4).
- OTC market listing.
What Are the Key Risks for BBBT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from larger companies with greater resources.
- Regulatory changes in the biopesticide and CBD markets.
- Negative profit and gross margins.
- Limited financial resources.
- OTC market listing.
What Threats Does BBBT Face?
- Competition from larger companies.
- Regulatory changes in the biopesticide and CBD markets.
- Fluctuations in commodity prices (hemp).
- Economic downturn affecting consumer spending.
What Are BBBT's Competitive Advantages?
- Proprietary plant-based biopesticide formulation for MiteXstream.
- Established brand recognition for Grizzly Creek Naturals in the CBD market.
- Participation in the Montana Hemp pilot program providing access to hemp cultivation.
- Focus on sustainable and environmentally friendly products appealing to conscious consumers.
What Does BBBT Do?
Black Bird Biotech, Inc., formerly known as Digital Development Partners, Inc., was rebranded in June 2021 to reflect its focus on biotechnology. The company develops, manufactures, and distributes a range of products, including MiteXstream, a plant-based biopesticide designed to eradicate spider mites, a common pest in agriculture and horticulture. This product represents a key offering in the company's portfolio, targeting the agricultural sector's need for environmentally friendly pest control solutions. In addition to its biopesticide products, Black Bird Biotech also manufactures and sells CBD-infused products under the Grizzly Creek Naturals brand. This line includes CBD oils, gummies, pet treats, and personal care products, catering to the growing market for CBD-based wellness solutions. The company also produces hand sanitizer gel and spray products. Furthermore, Black Bird Biotech participates in the Montana Hemp pilot program, growing industrial hemp for various applications. Based in Flower Mound, Texas, the company aims to leverage its biotech expertise to develop and market innovative products in both the agricultural and consumer wellness sectors. The company's evolution reflects a strategic shift towards biotechnology and a commitment to developing plant-based solutions.
What Products and Services Does BBBT Offer?
- Manufactures and distributes MiteXstream, a plant-based biopesticide.
- Sells CBD oils, gummies, and pet treats under the Grizzly Creek Naturals brand.
- Offers CBD-infused personal care products.
- Produces hand sanitizer gel and spray products.
- Grows industrial hemp under the Montana Hemp pilot program.
- Develops biotech products for agricultural and consumer markets.
How Does BBBT Make Money?
- Revenue from the sale of MiteXstream biopesticide to agricultural customers.
- Sales of Grizzly Creek Naturals CBD products through retail and online channels.
- Income from the cultivation and sale of industrial hemp.
- Potential revenue from licensing or partnering on its biotech products.
What Industry Does BBBT Operate In?
Black Bird Biotech operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for biopesticides and CBD products. The market for biopesticides is expanding as farmers seek sustainable alternatives to traditional chemical pesticides. The CBD market is also growing, fueled by increasing consumer awareness of the potential health benefits of CBD. However, the industry is highly competitive, with established players and new entrants vying for market share. Black Bird Biotech faces competition from larger companies with greater resources and established distribution networks. The company's success depends on its ability to differentiate its products and effectively market them to target customers.
Who Are BBBT's Key Customers?
- Farmers and agricultural businesses seeking biopesticide solutions.
- Consumers interested in CBD-based wellness products.
- Retailers and distributors of agricultural and consumer products.
- Manufacturers who use industrial hemp as a raw material.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Black Bird Biotech, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Argyle, US. The company is led by CEO Nelson Grist. BBBT has traded publicly since 2009.
Financial Health
Black Bird Biotech, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BBBT Financials
BBBT Latest News
No recent news available for BBBT.
BBBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BBBT.
Price Targets
Wall Street price target analysis for BBBT.
BBBT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BBBT; grades run from A+ (80-100) to F (below 30).
Leadership: Nelson Grist
CEO
Nelson Grist serves as the CEO of Black Bird Biotech, Inc., leading a small team of 4 employees. As CEO, he is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is critical to the company's success in the competitive biopesticide and CBD markets. Given the limited size of the company, he likely plays a hands-on role in all aspects of the business.
Track Record: Due to the limited information available, it is difficult to assess Nelson Grist's track record at Black Bird Biotech. The company's recent rebranding and focus on biotechnology suggest a strategic shift under his leadership. However, the company's negative profit and gross margins indicate significant challenges in achieving profitability. His success will depend on his ability to effectively manage costs, drive revenue growth, and navigate the regulatory landscape.
BBBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Black Bird Biotech may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Going concern risk.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and potential dilution.
- Research any legal or regulatory issues.
- Consult with a financial advisor.
- Existence of a physical address and contact information.
- Presence of a functional website.
- Publicly available press releases and investor information.
- Independent third-party verification of products or services.
- Active participation in industry events or associations.
BBBT Healthcare Stock FAQ
What do analysts say about BBBT stock?
As of 2026-03-17, there is no available analyst coverage for Black Bird Biotech, Inc. due to its OTC listing and small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be complete.
- Forward-looking statements are subject to risks and uncertainties.